Drug Trial Radar · NCT05977023
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 4, 2023
Primary completion
Nov 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- China Medical University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Science and Technology Council
- First posted
- Aug 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived stress. NMDA receptor (NMDAR) dysfunction is associated with BD-I, particularly its cognitive impairment and perceived stress. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of cognitive impairment and perceived stress in the patients with bipolar depression.
Conditions
- Bipolar I Disorder
Interventions
NMDAEDrug
Use of an NMDA enhancer for the treatment of bipolar depression
Placebo CapDrug
Use of placebo as a comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Visual Continuous Performance TestTime frame: week 0, 8
- Change in Wisconsin Card Sorting TestTime frame: week 0, 8
- Change in Logical Memory Test of the Wechsler Memory ScaleTime frame: week 0, 8
- Digit SpanTime frame: week 0, 8
- Spatial SpanTime frame: week 0, 8
- Category FluencyTime frame: week 0, 8
- Trail Marking ATime frame: week 0, 8
- WAIS-III Digit Symbol-CodingTime frame: week 0, 8
- Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0Time frame: week 0, 8
- Change in Perceived Stress Scale in Perceived Stress ScaleTime frame: week 0, 2, 4, 6, 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.